Canopy Growth Corporation Reports Third Quarter Fiscal Year 2016 Financial Results

Quarterly Revenues increased 41% over Q2 FY 2016; increased 5‑fold year over year

SMITHS FALLS, ON, Feb. 25, 2016 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSXV: CGC) today released its financial results for the third quarter of fiscal year 2016 ended December 31, 2015.  All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Third Quarter Fiscal 2016 Highlights

  • Revenues of $3.5 million, representing a 41% increase over Q2 2016 and a greater than 400% increase over the three-month period ended December 31, 2014
  • 462,000 grams sold, representing an increase of 45% over Q2 2016 and a greater than 430% increase over the three-month period ended December 31, 2014
  • Adjusted Product Contribution1 of $2.4 million or 70% of sales
  • Over 8,200 registered patients at December 31, 2015 compared to 6200 at the end of Q2 2016 and 1,800 at the end of December 31, 2014
  • Cash position of $19.7 million
  • Completed acquisition of MedCannAccess, providing the Company three physical community engagement centres in the highly populous Southern Ontario region

Subsequent to Third Quarter Fiscal 2016

  • Tweed Inc. ("Tweed") granted license by Health Canada to produce and sell Cannabis Oil Extracts
  • Tweed launched sale of 10:1 Cannabis OilsTM

"Our diversified client acquisition and best-in-class customer service helped drive significant growth in active registered customers and revenue," said Bruce Linton, Chairman & CEO, Canopy Growth. "Our revenues reached an important milestone, exceeded one million dollars per month in the third quarter."

Added Linton, "The intent from day one has been to build a scale of production and brands that would be of value in medical and possibly non-medical markets, for when the time came.  We are increasing our focus on brand clarity and market segmentation for Bedrocan and Tweed."

Revenue Review

Revenue for the third quarter ended December 31, 2015 was $3.5 million, representing a sequential increase of 41% over the second quarter ended September 30, 2015.  Third quarter 2016 revenues were over 400% higher than the revenues reported in the three months ended December 31, 2014.

Revenues for the nine months ended December 31, 2015 were $7.7 million.   

Product Sales Review

Total product sold in third quarter Fiscal 2016 was approximately 462,000 grams at an average price of $7.34 per gram.  In comparison, approximately 319,000 grams at an average price of $7.54 per gram were sold in the second quarter Fiscal 2016 and approximately 216,000 grams at an average price of $7.74 per gram were sold in the first quarter of 2016.  In the three months ended December 31, 2014, the Company sold approximately 87,000 grams at an average price of $7.04 per gram. 

Over the nine months of fiscal 2016 ended December 31, 2015, Canopy Growth has sold almost 1 million grams of Cannabis product.

Gross Margin Review

The gross margin, including the unrealized gain on changes in fair value of biological assets, in accordance with IFRS, was $2.8 million, or 79% of sales, for the three-month period ended December 31, 2015.  In the three months ended December 31, 2014, the reported gross margin on the same basis was 36% of sales. Year to date, the gross margin, inclusive of the unrealized gain on changes in fair value of biological assets was $16.3 million or 213% of sales, as compared to $1.1 million, or 45% of sales, last year for the same period.

Adjusted Product Contribution Review

The Company's "Adjusted Product Contribution"1 is a Non-GAAP metric used by management which adjusts the reported gross margin by excluding the fair value measurements as required by IFRS and measures the cost of sales for the grams actually sold in the period. Management believes this measure provides useful information as it reflects the gross margin based on the Company's weighted average cost per gram from seed to sale against the grams sold.  The resulting Adjusted Product Contribution is $2.4 million, or 70% of sales, in the third quarter ended December 31, 2015 and $5.0 million, or 65% of sales, on a year to date basis to December 31, 2015. 

Third Quarter Fiscal 2016 Operating Expense Review

For the three-month period ended December 31, 2015, Sales, branding and medical outreach and education costs were $1.4 million (three months ended December 31, 2014 - $729,000).

General and Administrative ("G&A") expenses were $2.0 million in the three-month period ended December 31, 2015 compared to $1.0 million in the comparison period ended December 31, 2014. The increase in G&A reflects the Company's growth from the early start-up of last year, building commercial capacity and capability as a public company and meeting all compliance requirements with Health Canada.

Third Quarter Fiscal 2016 Earnings Review

The Company reported a net loss of $3.3 million or $0.04 per basic share for the three months ended December 31, 2015, compared to a net loss of $2.6 million or $0.07 per basic share in the comparison quarter last year.

For the nine months ended December 31, 2015, net income was $1.6 million or $0.02 per basic share, compared to a net loss of $6.2 million or $0.15 per basic share in the nine months ended December 31, 2014.  The net income or loss was inclusive of the non-cash unrealized gain on changes in fair value of biological assets described above.

Third Quarter Fiscal 2016 Balance Sheet and Cash Flow Review

At December 31, 2015, the Company's cash, comprised of cash and cash equivalents totaled $19.7 million, representing a decrease of $1.7 million from March 31, 2015. The decrease is attributable to net proceeds from financings, including the "bought deal" common share offering in Q3 and the exercise of warrants and options, together totaling $20.6 million, primarily offset by $2.1 million used to repay a loan, $11.1 million used to fund operations, and investments in facility enhancements totaling $10 million.  Investments in facility enhancements include the build out of our Tweed Farms facility and the installation of equipment in our Tweed facility, in part required for the production of cannabis oil extracts.

The Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis documents have been filed with SEDAR and are available on www.sedar.com.  The basis of financial reporting in the Unaudited Condensed Interim Consolidated Financial Statements and Management's Discussion and Analysis documents has been revised to thousands of Canadian dollars, unless otherwise indicated.

Subsequent Events

Bedrocan True Compassionate Pricing

Bedrocan Canada ("Bedrocan") took an important step to making medical cannabis more affordable for all Canadian patients with a new price structure called True Compassionate Pricing. Under True Compassionate Pricing, all six cannabis varieties produced by Bedrocan Canada are priced at $5 per gram, making it the most affordable product line in Canada. Many Canadians who medicate with cannabis are doing so because traditional pharmaceutical drugs have not been as effective at treating their symptoms or have undesirable side effects. The decision to consume medical cannabis is made more complex due to the cost of the medicine.

Bedrocan's production methods have been refined over two decades to maximize yield and eliminate genetic variance from harvest  to harvest. As a result, Bedrocan is able to produce standardized varieties efficiently. With Bedrocan's facility operating at full capacity, Bedrocan is in a position to offer standardized varieties at a much lower price.

Tweed Cannabis Oil Extracts Supplemental License
On February 23, 2016, Tweed was granted a supplemental license by Health Canada to sell up to 350 kilograms of Cannabis Oil Extracts during the license period, which ends January 19, 2017.

Sales of 10:1 Cannabis OilsTM launched
On February 24, 2016, Tweed announced that the company had launched the sale of high‑quality 10:1 Cannabis Oils made with GMO-free, organic sunflower oil. Starting with oils made from single strains and slowly introducing high-quality oil products, Tweed's product line will meet the needs of Canadians managing a variety of symptoms. Starting with popular offerings of Argyle, Princeton and Birds Eye, Tweed will introduce new strain-specific 10:1 Cannabis Oils on an ongoing basis.  The new product line, 10:1 Cannabis Oils, will be sold in 100ml bottles equivalent to 10 dried grams of the same dried flower. Each 10 ml will contain the equivalent of 1 gram of the corresponding Tweed dried-flower variety. Creating a universal equivalency factor between flower and oil is a logical and simple way to ensure that Tweed customers can manage their dosing confidently.  Tweed chose to balance 10:1 Cannabis Oils with organic, non-genetically modified sunflower oil because it is versatile enough to cook or bake with, hypoallergenic, and even good to ingest on its own.

Federal Court Ruling

On February 24, 2016, the Federal Court released its decision in the case of Allard et al v. Canada. This case began as a result of the government's decision to repeal the Marihuana Medical Access Regulations ("MMAR") and enact the Marihuana for Medical Purposes Regulations ("MMPR").  This change overhauled the way that the government provides access to medical cannabis for patients across the country. The plaintiffs in the Allard case argued that the MMPR violates their Charter rights and the court, in a lengthy and detailed judgment, agreed with the plaintiffs and gave the government six months to amend the MMPR.  Canopy Growth's preliminary interpretation of the decision is as follows: i) the decision reaffirms the right of Canadians to access marijuana for medical purposes; ii) the decision stipulates that the MMPR, under which Canopy Growth subsidiaries Tweed, Tweed Farms and Bedrocan Canada are licensed producers, does not provide sufficient access to cannabis; iii) the decision gives the Canadian Federal Government a period of six months to determine how existing regulations should be amended to ensure that patients have the access to medical marijuana that they need; and iv) the current MMPR regulations remain in force.  Based on this preliminary interpretation, management does not believe the Allard decision will materially impact Canopy Growth.

Note 1: The Adjusted Product Contribution is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.  The Adjusted Product Contribution is reconciled and explained in Management's Discussion & Analysis under "Adjusted Product Contribution (Non-GAAP Measure)", a copy of which has been filed today on www.sedar.com.

Conference Call Details

Canopy Growth will host a conference call with Bruce Linton, CEO and Tim Saunders, CFO at 8:30 AM Eastern Time on February 25, 2016.

Calling Information
Toll Free Dial-In Number: 1-888-231-8191
International Dial-In Number (647) 427-7450
Conference ID: 55227314

Replay Information
A replay of the call will be accessible by telephone until 11:59 PM ET on March 24, 2016.
Toll Free Dial-in Number: 1-855-859-2056
Replay Password: 55227314

About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded medical marijuana company and the first geographically diversified producer with dual licenses under the Marihuana for Medical Purposes Regulations. Through its wholly owned subsidiaries, Tweed, Tweed Farms, and Bedrocan, the Company operates three state-of-the-art production facilities in Ontario and distributes marijuana across the country to Canadian patients managing a host of medical conditions. The Company is dedicated to educating healthcare practitioners, providing consistent access to high quality medication, conducting robust clinical research, and furthering the public's understanding of how marijuana is used for medical purposes. www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth Corporation, Tweed Inc., Tweed Farms Inc. or Bedrocan Canada Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include future operational and production capacity, the impact of enhanced infrastructure and production capabilities, and forecasted available product selection.  The forward-looking statements included in this news release are made as of the date of this news release and Canopy Growth Corp. does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 


Canopy Growth Corporation





Condensed consolidated statements of comprehensive (loss) income for the three and nine-month periods ended December 31, 2015 and 2014

(Expressed in CDN $000's except per share amounts)




(Unaudited)






Three months ended 

Nine months ended 


December 31,

December 31,

December 31,

December 31,


2015

2014

2015

2014


$

$

$

$






Revenue

3,481

641

7,657

1,146







Unrealized gain on changes in fair value of biological assets

(9,013)

(939)

(26,768)

(3,196)


Inventory expensed to cost of sales

3,784

239

7,954

629


Production costs

5,954

1,111

10,173

3,197

Cost of sales, net of the unrealized gain on changes in fair value of biological assets

725

411

(8,641)

630

Gross margin, including the unrealized gain on changes in fair value of biological assets

2,756

230

16,298

516






Sales and marketing

1,372

729

3,253

1,880

Research and development

192

41

441

160

General and administration

1,962

1,035

5,619

2,286

Acquisition costs

16

-

1,155

-

Share-based compensation expense 

1,162

908

2,107

2,080

Amortization

755

173

1,475

356


5,459

2,886

14,050

6,762

(Loss) income from operations

(2,703)

(2,656)

2,248

(6,246)






Interest income/(expense)

(102)

18

(111)

71

Change in fair value of acquisiton consideration related liabilities 

(741)

-

(741)

-


(843)

18

(852)

71

(Loss) income and comprehensive (loss) income before taxes

(3,546)

(2,638)

1,396

(6,175)






Income tax recovery

230

-

230

-

Net (loss) income and comprehensive (loss) income after taxes

(3,316)

(2,638)

1,626

(6,175)






Net (loss) income per share, basic:

$(0.04)

$(0.07)

$0.02

$(0.15)






Weighted average number of outstanding common shares:





Basic  

93,355,021

40,320,097

69,356,439

39,859,805






Net (loss) income per share, diluted:

$(0.04)

$(0.07)

$0.02

$(0.15)






Weighted average number of outstanding common shares:





Diluted 

93,355,021

40,320,097

76,688,213

39,859,805

 


Canopy Growth Corporation

Condensed consolidated statements of financial position as at December 31, 2015 and March 31, 2015

(Expressed in CDN $000's)

(Unaudited)


December 31,

March 31,


2015

2015


$

$




Assets



Current assets




Cash and cash equivalents

19,719

21,446


Restricted short-term investment

296

10


Accounts receivable

833

342


HST recoverable

618

431


Biological assets

2,887

2,028


Inventory

22,808

4,355


Prepaid expenses

995

764


48,156

29,376




Property, plant and equipment 

39,614

17,745

Leasehold construction in process 

3,725

615

Intangible assets 

58,051

38


149,546

47,774




Liabilities



Current liabilities




Accounts payable and accrued liabilities

4,487

4,278


Current portion of long-term debt

364

247


4,851

4,525


Long-term debt

3,610

1,669


Deferred tax liability

7,204

-


Acquisition consideration related liabilities

1,636

-


Other long-term liabilities

198

171


17,499

6,365




Shareholders' equity




Share capital

137,301

49,826


Share-based reserve

3,331

1,724


Warrants

69

138


Deficit

(8,654)

(10,279)


132,047

41,409


149,546

47,774

Canopy Growth Corporation

Condensed consolidated statements of cash flows for the three and nine-month periods ended December 31, 2015 and 2014

(Expressed in CDN $000's)

(Unaudited)


Three months ended

Nine months ended


December 31,

December 31,

December 31,

December 31,


2015

2014

2015

2014


$

$

$

$

Net inflow (outflow) of cash related to the following activities:











Operating







Net income (loss)

(3,316)

(2,638)

1,626

(6,175)



Items not affecting cash:








Amortization of property, plant and equipment

619

171

1,334

348




Amortization of intangible assets

136

2

141

8




Unrealized gain on change in fair value of biological assets

(9,013)

(939)

(26,768)

(3,196)




Share-based compensation

1,162

908

2,107

2,080




Income tax recovery

(230)

-

(230)

-




Change in fair value of acquisition consideration related liabilities

741

-

741

-




Listing expense

-

-

-

30



Changes in non-cash operating working capital items

5,728

436

9,907

728


(4,173)

(2,060)

(11,142)

(6,177)







Financing







Increase in other long-term liabilities

-

-

27

-



Issuance of common shares from financing round

14,376

-

14,376

15,000



Exercise of stock options

235

215

242

325



Exercise of warrants

6,858

-

7,418

-



Share issue costs

(1,267)

7

(1,457)

(1,518)



(Repayment)/issuance of long-term debt

(1,925)

1,875

(1,985)

1,835


18,277

2,097

18,621

15,642







Investing







Increase in restricted short-term investment

-

-

(286)

-



Purchase of leasehold construction in process

(964)

(2,311)

(5,525)

(6,200)



Purchase of intangible assets

-

(7)

-

(21)



Tweed Farms purchase liability

-

-

-

(1,500)



Purchase of property, plant and equipment

(1,301)

(302)

(4,449)

(3,670)



Acquisition of subsidiaries

154

-

1,054

-


(2,111)

(2,620)

(9,206)

(11,391)






Net cash inflow, (outflow)

11,993

(2,583)

(1,727)

(1,926)

Cash and cash equivalents, beginning of period

7,726

8,357

21,446

7,700

Cash and cash equivalents, end of period

19,719

5,774

19,719

5,774

 

Canopy Growth Corporation
















Non-GAAP Measure (In CDN$000's, except gram amounts)


Three Months Ended


Three Months Ended


Three Months Ended


Nine Months Ended

Adjusted Product Contribution1  


June 30,


September 30,


December 31,


December 31,



2015


2015


2015


2015










Weighed average cost per gram

$

3.16

$

$2.92

$

2.29

$

2.68

Grams sold in the period


215,929


318,572


461,544


996,045










Revenue

$

1,710

$

2,466

$

3,481

$

7,657


Adjusted cost of sales2


(682)


(931)


(1,059)


(2,672)

Adjusted Product Contribution

$

1,028

$

1,535

$

2,422

$

4,985

Adjusted Product Contribution percentage of sales


60.1%


62.2%


69.6%


65.1%










As compared to the Gross Margin per IFRS:


















Gross margin, including the unrealized gain on changes in fair value of biological assets as reported on the Statements of Comprehensive Loss

$

4,095

$

9,447

$

2,756

$

16,298










Gross margin percentage of sales, including the unrealized gain on changes in fair value of biological assets as reported on the Statement of Comprehensive Loss


239.5%


383.1%


79.2%


212.9%










Notes:



1

The Adjusted Product Contribution removes the fair value measurements required under IFRS and recognizes the cost of sales based on the weighted average cost per gram to produce and sell product in the period.

2

Based on the weighted average of cost per gram from seed to sale of $2.29 per gram in the third quarter and $2.68 per gram for the year to date and applied to the number of grams sold in the period.

 

SOURCE Canopy Growth Corporation

For further information: For media inquiries: Jordan Sinclair, Communications Manager, Canopy Growth Corporation, jordan.sinclair@canopygrowth.com, 613-706-2185 ex 309; For investor inquiries: Tyler Burns, Investor Relations, Canopy Growth Corporation, tyler.burns@canopygrowth.com, 613-706-2185 ex 122

RELATED LINKS
http://canopygrowth.com/

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890